anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An aqueous or non-aqueous preparation comprising cationic agents to neutralize a negative charge thereby relieving tension in the skin and preventing moisture from escaping. It relieves static-tension in the skin thereby reducing the distance between the pores. The difference between the present invention and other water based skin conditioners is the amount of cationic agents used. The present invention utilizes much more of these ingredients than other commercial products. This produces the unexpected result of neutralizing the charge on the skin and relieving tension, softening and moisturizing the skin. In its most basic form, it contains no moisturizing or other skin conditioning agents. These products can be added to the Present Invention, or alternatively, the present invention may be used as an additive to most currently available commercial aqueous and non-aqueous based skin moisturizers for a synergistic skin softening effect.
Bipolar disorder (BD) is a serious, disabling, and highly recurrent illness that is disproportionately represented in the criminal justice system. BD increases risk for several adverse outcomes for prisoners, including mood instability, suicide attempts, substance use relapse, and high rates of repeat incarceration. Despite these serious negative consequences, up to 70% of prisoners with BD do not receive mental health treatment upon prison release. Lack of engagement in ongoing mental health treatment for BD upon community re-entry represents one potent factor that perpetuates risk for adverse outcomes, and consequences of untreated BD (e.g., impulsivity, substance use) may greatly exacerbate difficulties in establishing stable living conditions (e.g., adequate housing, legal employment) at community re-entry. Thus, there is a critical need for interventions to facilitate engagement with treatment for BD during this vulnerable transition.

To that end, the primary aim of this study is to develop and establish the feasibility and acceptability of the Community treatment Adherence at Re-Entry (CARE) program. CARE is an innovative intervention that will combine evidence-based cognitive-behavioral, family, and telephone outreach strategies to promote treatment engagement and improve clinical outcomes for prisoners with BD during the period of community re-entry. CARE will include 3 individual and 1 family session, followed by 11 brief telephone contacts for up to 6 months post-release. Given its moderate intensity, adjunctive nature, use of community mental health counselors, and use of telephone administration for post-release follow-up, CARE has been designed with an eye toward community implementation. Its proposed mechanisms of action (i.e., increasing values-action consistency, enhancing social supports, and linkage to community treatment services) are further well matched to the practical and clinical needs of re-entering individuals.

The aim of this research is to conduct a small open trial (n=12) of the CARE intervention. Assessments will occur at baseline, immediately pre-release, 4 weeks post-release, and 24 weeks post-release (post-treatment). This study will examine the feasibility and acceptability of CARE (e.g., uptake, adherence to, and completion of the CARE intervention, satisfaction with the intervention, understanding of intervention principles) and of this research design. This study will also examine treatment effects (within relevant confidence intervals) on outcomes (e.g., mood symptoms). Change in potential mechanisms (i.e., values-action consistency derived from intervention principles) will be examined.
The invention relates to a drug for treating lepra alphos and a preparation method thereof. The drug is prepared from 15g of dried rehmannia root, 9g of angelica root, 9g of fructus forsythiae, 9g of clean insect coat, 6g of cortex dictam, 6g of bombyx batryticatus, 4g of radix sileris, 15g of coixseed, 12g of Angelica sinensis, 15g of radix scrophulariae and suitable amount of powdery realgar, radix scrophulariae, weeds, borneol and fructus corni. The drug for treating lepra alphos and preparation method thereof use traditional Chinese medicine for the treatment. The materials can be widely accessible with low cost. The drug can root out the diseases easily with no side effects. Coordinated by external scrubbing, the drug can both cure the superficial symptoms and root out the disease, and hugely enhance the effect of lepra alphos treatment.
The gene responsible for the autosomal recessive mouse obesity mutation tub was identified by positional cloning. The homologous human gene is also provided. The genes are used to produce tubby protein; in screening for compositions that modulate the expression or function of the tubby protein; and in studying associated physiological pathways. The DNA is further used as a diagnostic for genetic predisposition to obesity, retinal degeneration or cochlear degeneration. The mutation responsible for the tub phenotype is a G to T transversion that abolishes a donor splice site in the 3' coding region and results in a larger transcript containing the unspliced intron. A second, prematurely truncated transcript arises from the introduction of a premature polyadenylation site in the unspliced intron.
Paraneoplastic cerebellar and brainstem disorders are a heterogeneous group that requires prompt recognition and treatment to help prevent irreversible neurologic injury. Paraneoplastic cerebellar degeneration is best characterized by Yo antibodies in patients with breast or ovarian cancer. Tr (DNER) antibodies in patients with Hodgkin lymphoma can also present with a pure cerebellar syndrome and is one of the few paraneoplastic syndromes found with hematological malignancy. Opsoclonus-myoclonus-ataxia syndrome presents in both pediatric and adult patients with characteristic clinical findings. Other paraneoplastic brainstem syndromes are associated with Ma2 and Hu antibodies, which can cause widespread neurologic dysfunction. The differential for these disorders is broad and also includes pharmacological side effects, infection or postinfectious processes, and neurodegenerative diseases. Although these immune-mediated disorders have been known for many years, mechanisms of pathogenesis are still unclear, and optimal treatment has not been established.
PURPOSE: To obtain an inhibitor of superoxide production, containing a 1-naphthol derivative as an active ingredient, capable of manifesting excellent inhibiting actions on the O2 <-> production by human neutrophils, etc., and utilizable as a medicine such as an antiinflammatory agent or a therapeutic agent for autoimmune diseases. CONSTITUTION: This inhibitor contains 0.1-10wt.% compound of formula I [ring A is benzene, pyridine, thiazole ring, etc.; R<1> is H, a lower alkyl or an aromatic group; R<2> is a halogen or a lower alkyl; R<3> and R<4> are each H, a halogen, nitro, amino or a lower alkyl; (m) is 0-2; (n) is 1-4, etc.] as an active ingredient. The active ingredient can be prepared into an oral agent, a parenteral injection or a troche, a mucosal administering agent such as a suppository or a preparation for external use such as an ointment or an application agent. The daily dose thereof for an adult is 1-1000mg administered in divided 2-3 portions. The compound of formula I is new and can be obtained by reacting a compound of formula II with α-tetralone or its corresponding derivative in the presence of a base.
This study proposes a 2-arm, RCT to test and compare adherence-enhanced Trauma Informed Cognitive Behavioral Therapy (TI-CBTe) to usual care on ART adherence among HIV+ Rwandan youth. Based on a well-grounded theoretical framework, TI-CBTe blends a culturally adapted empirically-supported intervention (TI-CBT) with strategies to increase ART adherence by reducing depression, trauma, and gender based violence (GBV). 350 HIV+ 14-21 year olds will be randomly assigned to TI-CBTe or usual care and the intervention will be delivered in small groups of 8 - 10 over eight consecutive Sundays. Adult caregivers (where available) will participate in two sessions to address adherence support for youth. Caregivers and youth will complete assessments at baseline, 6 and 12 months. Consistent with the Indigenous Leader Outreach Model (ILOM), HIV+ young adults who are \> 95% ART adherent will be trained to deliver TI-CBTe. An intent-to-treat analysis will be used and a combination of regression techniques and other inferential statistical tests for contrasting means and proportions. Treatment effects on adherence and mediators for youth participants will be examined, as well as indigenous youth leaders. Treatment outcomes will be analyzed using logistic and linear multiple regression models examining effects at 6- and 12- months separately, as well as a combined model with random effects for repeated measurements across time.

Participants will be recruited from two clinics: WE-ACTx For Hope and Central University Hospital of Kigali (CHUK), which are the primary providers of HIV care for infected adolescents, and both have long-standing relationships with the community. Youth and caregivers will be invited to meet with research staff if they are interested to inform them about the project and request permission to be contacted by the research team. The assent/consent forms will be reviewed with IYL, youth and caregivers, and trained staff will administer questionnaires and interviews. Both sites have a staff psychologist who will provide clinical backup in cases of mental health distress. Consent/assent forms will state the exceptions to confidentiality, and where a youth reports child abuse or neglect or suicidal ideation or attempts, the psychologist will be consulted. Indigenous youth leaders (IYL), youth and caregivers will each complete the baseline and two follow-up assessments. A month before follow-ups, IYL, youth and caregivers will be contacted to request their participation in the next wave of data collection. Transportation will be offered and interviews will be conducted at the clinics in a confidential location.
Clinically significant liver injury has occurred in patients treated with GILENYA in the postmarketing setting. Signs of liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, have occurred as early as ten days after the first dose and have also been reported after prolonged use. Cases of acute liver failure requiring liver transplant have been reported. 

In 2-year placebo-controlled clinical trials in adult patients, elevation of liver enzymes (ALT, AST, and GGT) to 3-fold the upper limit of normal (ULN) or greater occurred in 14% of patients treated with GILENYA 0.5 mg and 3% of patients on placebo. Elevations 5-fold the ULN or greater occurred in 4.5% of patients on GILENYA and 1% of patients on placebo. The majority of elevations occurred within 6 to 9 months. In clinical trials, GILENYA was discontinued if the elevation exceeded 5 times the ULN. Serum transaminase levels returned to normal within approximately 2 months after discontinuation of GILENYA. Recurrence of liver transaminase elevations occurred with rechallenge in some patients. 

Prior to starting treatment with GILENYA (within 6 months), obtain serum transaminases (ALT and AST) and total bilirubin levels. Obtain transaminase levels and total bilirubin levels periodically until two months after GILENYA discontinuation. 

Patients should be monitored for signs and symptoms of any hepatic injury. Measure liver transaminase and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. In this clinical context, if the patient is found to have an alanine aminotransferase (ALT) greater than three times the reference range with serum total bilirubin greater than two times the reference range, treatment with GILENYA should be interrupted. Treatment should not be resumed if a plausible alternative etiology for the signs and symptoms cannot be established, because these patients are at risk for severe drug-induced liver injury. 

Because GILENYA exposure is doubled in patients with severe hepatic impairment, these patients should be closely monitored, as the risk of adverse reactions is greater [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
In previous studies, CST has been identified as having an immunostimulatory effect on Caenorhabditis elegans and macrophage of rats. Here, we further investigated its immunomodulatory effects on human peripheral blood mononuclear cells (PBMCs). LPS-stimulated PBMCs inflammatory model was established. Flow cytometry was applied to measure phagocytosis of PBMCs. Cytokine mRNA and protein expression levels of LPS-stimulated PBMCs with or without CST were measured by qRT-PCR and ELISA. The transcriptomic profile of CST-treated PBMCs was investigated by RNA-sequencing. Gene Ontology (GO) and Kyoto Encylopedia of Genes and Genomes (KEGG) were applied to find potential signalling pathways. PBMCs showed a significant increase in phagocytic activity at 6 h after being incubated with CST at the concentration of 10 μg/mL. In the presence of LPS, CST maintained and promoted the expression of TNF-α and chemokine CCL24. The content of pro-inflammatory cytokines, such as IL-1β, IL-6 and IFN-γ, which were released from LPS-stimulated PBMCs, was reduced by CST at 6 h. Anti-inflammatory cytokines, such as IL-4, IL-13 and TGF-β1, were significantly increased by CST at 24 h. A total of 277 differentially expressed immune-related genes (DEIRGs) were detected and cytokine-cytokine receptor interaction was highly enriched. CST presented obvious anti-inflammatory and immunoregulatory effects in LPS-induced PBMCs inflammatory model not only by improving the ability of PBMCs to clear pathogens but also by decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokines. And the mechanism may be related to cytokine-cytokine receptor interaction.
PROBLEM TO BE SOLVED: To obtain the subject composition having high stability of orthophthalaldehyde in high concentration, manifesting reduced degradation, polymerization and discoloring and being liquid at normal temperature by including predetermined amounts of water and water soluble aliphatic alcohol to orthophthalaldehyde. SOLUTION: The composition comprises (A) 100 pts.wt. of orthophthalaldehyde, (B) 1-300 pts.wt. of water, preferably at pH of 4-8, (C) 1-500 pts.wt. of water soluble aliphatic alcohol(e.g.; polyethylene glycol 200, ethylene glycol monomethyl ether and the like). The prescribed composition is preferably prepared by directly adding water and a water soluble aliphatic alcohol to the synthesized orthophthalaldehyde in a melt state.
Germline (GL) predisposition to acute myeloid leukemia (AML) has been established as an independent disease entity in the latest World Health Organization classification. Following the American College of Medical Genetics and Genomics guidelines, GL variants were interpreted as causal if they were classified as "pathogenic." GL predisposition can be divided into three groups with different phenotypes, and play an important role in the pathogenesis of adult-onset AML. The clinical course and age of onset of myeloid neoplasms varied considerably for each gene. For example, patients with GATA2 GL variants develop AML before the age of 30 along with bone marrow failure, whereas those with DDX41 GL variants tend to develop AML after the age of 50 without any preceding hematological abnormalities or organ dysfunction. A comprehensive analysis of adult-onset myelodysplastic syndromes in transplant donors showed a 7% frequency of pathogenic GL variants, with DDX41 being the most frequent gene mutation at approximately 3.8%. Future research on GL predisposition at any age of myeloid neoplasm onset will assist in early and accurate diagnosis, development of effective treatment strategies, and selection of suitable donors for stem cell transplantation.
PURPOSE: To extract Acer nikoense in a short time and in high extraction efficiency, to improve workability and to obtain the subject sufficiently sterilized essence by using a high-pressure pot for extraction of essence of Acer nikoense and sterilization of the extracted essence. CONSTITUTION: First, a raw material comprising dried Acer nikoense with bark and water in the ratio of preferably 1,700-1,800 pts.wt. of water based on 100 pts.wt. of the raw material are put in a high-pressure container and the raw material is extracted at >=100 deg.C, preferably 103 to 110 deg.C and 2.5 to 3.5 hours to give essence of Acer nikoense. Then the raw material is removed and the extracted solution is heated and sterilized at >=121 deg.C, preferably 125 to 130 deg.C and the insoluble material is removed by filtration to give the objective essence. In the sterilization, the extracted solution is preferably evaporated until the amount of the water reaches 1,600-1,650 pts.wt.
Eszopiclone, like other hypnotics, has CNS-depressant effects. Because of the rapid onset of action, eszopiclone should only be ingested immediately prior to going to bed or after the patient has gone to bed and has experienced difficulty falling asleep. Patients receiving eszopiclone should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination (e.g., operating machinery or driving a motor vehicle) after ingesting the drug, and be cautioned about potential impairment of the performance of such activities on the day following ingestion of eszopiclone. Eszopiclone, like other hypnotics, may produce additive CNS-depressant effects when coadministered with other psychotropic medications, anticonvulsants, antihistamines, ethanol, and other drugs that themselves produce CNS depression. Eszopiclone should not be taken together with alcohol. Dose adjustment may be necessary when eszopiclone is administered with other CNS-depressant agents, because of the potentially additive effects.
A portable, reusable medication dispensing assembly which has communication capability to improve medication adherence is disclosed. An electromechanical apparatus sequentially delivers dosage form packages from a compartment in a housing to a dose-ready area in the housing. A microprocessor-based controller is reprogrammable with contact and prescription data. The controller controls the electromechanical apparatus to sequentially deliver the dosage form packages at prescribed times or time intervals to the dose-ready area based on the prescription data. The controller generates and stores a set of event data based on when the dosage form packages are ready to be released in the dose-ready area and whether and when the dosage form packages have been released in the dose-ready area. Communication apparatus is capable of wirelessly transmitting the event data via a publicly-accessible network to a remote database and to wirelessly transmit event notifications via the network based on the prescription and contact data.
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to radiation diagnostics, and can be used to assess changes in cerebral perfusion. A method for evaluating changes in cerebral perfusion involves single-photon emission computed tomography of the brain, constructing graphs of radiopharmaceutical accumulation by cerebral sections and perfusion analysis of cerebral tissue. Evaluation of the level of cell perfusion is carried out simultaneously on the area of the entire brain section, for this purpose, the analyzed section is placed into an image processing program, and a "lasso" type instrument is used to extract an image of the brain along the perimeter. Then, a tone curve is automatically arranged, which is transformed by dividing the image into right and left halves of the diagram with superposition of mirror projections on each other, thereby obtaining two separate images, each of which contains a straight and mirror projection of the diagram. Using the software, the obtained images are aligned so that the point of intersection of the diagonal lines is in the center of the image, while simultaneously reducing the transparency of the superimposed image by 50%. Final image with lower conditional triangle layer is stored for analysis. Preoperative and postoperative cerebral perfusion changes are evaluated by comparing the perfusion level diagram results in the selected cerebrum cut with the cell perfusion rate pattern for the corresponding brain section, wherein in the preoperative period, if the dense coloring area is higher than the norm boundary by the perfusion rate template and when the weak color area is shifted beyond the conditional triangle, the quantitative perfusion reduction is determined, if the area of dense and weak color within the limits of the standard perfusion pattern, perfusion is determined within the limits of standard values. In the postoperative period, if the area of dense coloring has increased relative to the norm by the perfusion rate template and the area of weak coloring has increased and shifted beyond the conditional triangle, then quantitative reduction of perfusion is determined, and if the area of dense coloring is within normal limits or is approximated to the norm by the perfusion pattern, if the weak color weak region is shifted to the area of the conditional triangle, and the area of weak coloring is within the norm or is approximated to the norm by the perfusion rate pattern, perfusion restoration is determined.EFFECT: invention provides a graphical assessment of changes in regional cerebral blood flow to assess changes in cerebral perfusion on the area of the whole brain section, possibility of assessing the quality of perfusion irrespective of the method of imaging.1 cl, 15 dwg, 3 ex
BACKGROUND: Kernel dehydration is an important factor for the mechanized harvest in maize. Kernel moisture content (KMC) and kernel dehydration rate (KDR) are important indicators for kernel dehydration. Although quantitative trait loci and genes related to KMC have been identified, where most of them only focus on the KMC at harvest, these are still far from sufficient to explain all genetic variations, and the relevant regulatory mechanisms are still unclear. In this study, we tried to reveal the key proteins and metabolites related to kernel dehydration in proteome and metabolome levels. Moreover, we preliminarily explored the relevant metabolic pathways that affect kernel dehydration combined proteome and metabolome. These results could accelerate the development of further mechanized maize technologies.
RESULTS: In this study, three maize inbred lines (KB182, KB207, and KB020) with different KMC and KDR were subjected to proteomic analysis 35, 42, and 49 days after pollination (DAP). In total, 8,358 proteins were quantified, and 2,779 of them were differentially expressed proteins in different inbred lines or at different stages. By comparative analysis, K-means cluster, and weighted gene co-expression network analysis based on the proteome data, some important proteins were identified, which are involved in carbohydrate metabolism, stress and defense response, lipid metabolism, and seed development. Through metabolomics analysis of KB182 and KB020 kernels at 42 DAP, 18 significantly different metabolites, including glucose, fructose, proline, and glycerol, were identified.
CONCLUSIONS: In sum, we inferred that kernel dehydration could be regulated through carbohydrate metabolism, antioxidant systems, and late embryogenesis abundant protein and heat shock protein expression, all of which were considered as important regulatory factors during kernel dehydration process. These results shed light on kernel dehydration and provide new insights into developing cultivars with low moisture content.